Journal of the American Heart Association

FEBRUARY 26, 2025

BackgroundAbdominal aortic aneurysm (AAA) is a severe aortic disease for which no pharmacological interventions have yet been developed. Colocalization analysis pinpointed 13 proteins with strong evidence of colocalization with AAA.

Aneurysm 40

Aneurysm Risk Factors Aortic Obesity 40

Stroke Journal

JANUARY 30, 2025

We have previously shown that apart from common vascular risk factor modification, adipose tissue-specific factors, such as adiponectin, may mediate the relationship between body fat and vascular risk.

Pharmacology 40

Pharmacology Circulation Coronary Artery Disease Risk Factors 40

DAIC

JUNE 7, 2024

They also theorize that other risk factors for CAVD, such as high blood levels of lipoprotein, can contribute to calcification both directly and indirectly through the mechanisms that involve amyloid accumulation. “We

Aortic valve 105

Aortic valve Aortic Heart Valves Pharmacology 105

Hypertension Journal

AUGUST 5, 2024

Hypertension is a leading risk factor for cardiovascular morbidity and mortality. Despite the widespread availability of both pharmacological and lifestyle therapeutic options, blood pressure control rates across the globe are worsening. Hypertension, Ahead of Print.

Hypertension 77

Hypertension Blood Pressure Pharmacology Risk Factors 77

Dr. Paddy Barrett

APRIL 5, 2024

Primordial prevention is changing the environment around you so you do not develop the risk factors for heart disease and, by extension, do not get the disease early in life. Blood Pressure Control High blood pressure is the risk factor associated with the greatest number of deaths worldwide. J Am Heart Assoc.

Heart Disease 119

Heart Disease Coronary Artery Disease Heart Attack Heart attacks 119

International Journal of Cardiovascular Sciences

MARCH 13, 2023

The term cardiometabolic risk describes the chances that a person has of damaging the cardiovascular system when one or more risk factors appear together. These factors include obesity, dyslipidemia, hypertension, and insulin resistance — also known as metabolic syndrome.

Pharmacology 52

Pharmacology Article Obesity Risk Factors 52

Frontiers in Cardiovascular Medicine

AUGUST 6, 2024

Despite significantly improving atherogenic dyslipidaemia, the most recent clinical trial outcome has cast doubt on the utility of pharmacologically lowering triglyceride concentrations using fibrates. Results from pharmacologically lowering triglyceride are conflicting.

Cardiovascular Disease 52

Cardiovascular Disease Pharmacology Cholesterol Risk Factors 52

Stroke Journal

FEBRUARY 1, 2024

Traumatic brain injury (TBI) afflicts 70 million people worldwide annually and is the 3rd overall risk factor for developing Alzheimer's disease (AD), behind genetics and aging. Stroke, Volume 55, Issue Suppl_1 , Page ATP312-ATP312, February 1, 2024.

Pharmacology 40

Pharmacology Risk Factors Strokes Stroke 40

The British Journal of Cardiology

NOVEMBER 29, 2023

The key risk factor for cardioembolic stroke is atrial fibrillation or flutter, and oral anticoagulation (OAC) is recommended in all but the lowest-risk patients with evidence of these arrhythmias. Risk factors for thrombotic stroke overlap strongly with those for other atherosclerotic cardiovascular diseases (ASCVDs).

Strokes 40

Strokes Stroke Risk Factors Blood Pressure 40

DAIC

MAY 16, 2024

Implementation of a multispecialty care team approach, including expertise in risk factor management, guideline directed medical therapies, wound and foot care and endovascular and surgical revascularization procedures, may improve outcomes for people with PAD. and Global Data From the American Heart Association.

Peripheral Arterial Disease 105

Peripheral Arterial Disease Exercise Ischemia Quality of Life 105

Frontiers in Cardiovascular Medicine

MARCH 4, 2024

The complex development of atherosclerosis manifests as intimal plaque which occurs in the presence or absence of traditional risk factors. Atherosclerotic coronary artery disease (CAD) is the causal pathological process driving most major adverse cardiovascular events (MACE) worldwide.

Plaque 59

Plaque Coronary Artery Disease Blood Pressure Cardiovascular Disease 59

Heart BMJ

MAY 10, 2024

1 While much effort has been directed at pharmacological and interventional techniques to improve outcomes for those living with these conditions, less has been directed towards identifying factors associated with increased incident risk of AF and non-AF arrhythmias, and strategies to ameliorate them.

Arrhythmia 40

Arrhythmia Myocardial Infarction Atrial Fibrillation Heart Failure 40

DAIC

MAY 21, 2024

The study, “Comprehensive Cardiovascular Risk Factor Control with a Mobile Health Cardiovascular Risk Self-Management Program,” highlights the potential use of digital health technology in the comprehensive control of risk factors for cardiovascular disease (CVD), the leading cause of death and disability in the United States.

Blood Pressure 52

Blood Pressure Cholesterol Risk Factors BMI 52

DAIC

APRIL 11, 2024

Optimal medical therapy for coronary artery disease includes lifestyle modifications and intensive pharmacologic interventions, according to the contemporary guideline directed medical therapy for secondary prevention. Half of the participants were randomly assigned to receive PCI plus medical therapy and half received medical therapy alone.

Plaque 111

Plaque Heart Attack Heart attacks Coronary Artery Disease 111

ADN Center of Excellence

SEPTEMBER 2, 2024

From advances in pharmacological treatments to innovative procedures like catheter ablation, the landscape of AFib treatment is continually evolving. Key Considerations for AFib Management Effective management of AFib requires a comprehensive approach that includes accurate diagnosis, risk stratification, and individualized treatment plans.

AFIB 59

AFIB Atrial Fibrillation Innovation Heart Rhythm 59

Hypertension Journal

OCTOBER 10, 2023

Considerable advances in our understanding of the biological mechanisms of aging have been made; yet, cardiovascular disease remains the leading cause of death in the United States urging a continued search for novel risk factors to target for preventing and treating disease.

Cardiovascular Disease 40

Cardiovascular Disease Risk Factors Pharmacology Research 40

Circulation

NOVEMBER 11, 2024

While it is known to increase serotonin levels in the brain and gastrointestinal tract, its pharmacology remains largely unexplored. After adjusting for conventional risk factors, the association between 5-HTP and calcification remained significant (p < 0.05).Conclusion:Higher

Kidney Disease 40

Kidney Disease Risk Factors Pharmacology Diabetes 40

ADN Center of Excellence

SEPTEMBER 2, 2024

From advances in pharmacological treatments to innovative procedures like catheter ablation, the landscape of AFib treatment is continually evolving. Key Considerations for AFib Management Effective management of AFib requires a comprehensive approach that includes accurate diagnosis, risk stratification, and individualized treatment plans.

AFIB 52

AFIB Atrial Fibrillation Innovation Heart Rhythm 52

Frontiers in Cardiovascular Medicine

FEBRUARY 27, 2024

Implementing preventive programs and increasing the control of cardiovascular risk factors may have a significant social and health impact by helping to reduce mortality and costs for the Spanish National Health System.

Cardiovascular Disease 45

Cardiovascular Disease Peripheral Arterial Disease Drug Costs Myocardial Infarction 45

Journal of the American Heart Association

DECEMBER 12, 2023

BackgroundCardiac hypertrophy (CH) is a well‐established risk factor for many cardiovascular diseases and a primary cause of mortality and morbidity among older adults. Currently, no pharmacological interventions have been specifically tailored to treat CH. Journal of the American Heart Association, Ahead of Print.

Pharmacology 40

Pharmacology Aortic Cardiac Function Risk Factors 40

DAIC

JANUARY 23, 2024

11 Despite the link between inflammation and cardiovascular disease has been proven by extensive research, most physicians have focused on treating high-risk patients with lipid lowering therapies including statin therapy.1,12,13 mg) to reduce the risks of heart attack, stroke, coronary revascularization, and CV death.29 Circulation.

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111

Stroke Journal

FEBRUARY 1, 2024

Hyperhomocysteinemia (Hhcy), a metabolic disorder is recognized as a risk factor for ischemic stroke. In a subset of Hhcy rats, NVP-AAM077, a pharmacological inhibitor of GluN2A-NMDAR was injected intravenously at the onset of stroke. Stroke, Volume 55, Issue Suppl_1 , Page AWP322-AWP322, February 1, 2024.

Ischemia 40

Ischemia Pharmacology Strokes Stroke 40

Journal of Cardiovascular Pharmacology

MARCH 4, 2024

Treatment of risk factors such as diabetes and cigarette smoking can benefit patients with PAD. Treatment of risk factors such as diabetes and cigarette smoking can benefit patients with PAD. Patients should have adequate blood pressure and lipid control to decrease clinical manifestations and symptoms of PAD.

Peripheral Arterial Disease 40

Peripheral Arterial Disease Blood Pressure Risk Factors Nursing 40

Cardiometabolic Health Congress

AUGUST 30, 2024

These conditions often intersect, sharing common risk factors and underlying mechanisms. Pharmacological Interventions : Use of antihypertensive medications, lipid-lowering agents, and antidiabetic drugs. Surgical and Procedural Interventions : Including bariatric surgery and revascularization procedures.

Cardiac Rehabilitation 52

Cardiac Rehabilitation Heart Failure Quality of Life Aortic 52

Journal of Cardiovascular Pharmacology

AUGUST 20, 2024

Cox proportion hazards regression models were used to examine the effect of SGLT2I and risk factors on the risk of developing ED, presented as a hazard ratio (HR) with a 95% confidence interval (CI). 159773 DM patients using SGLT2I and 159773 PS-matching DM patients who had never used SGLT2I was included.

Diabetes 40

Diabetes Risk Factors Article 40

Journal of Cardiovascular Pharmacology

AUGUST 9, 2023

Included is an up-to-date review of the current and rapidly evolving literature on CV risk in patients with IMIDs on JAKi therapy, including identification of potential risk factors for future VTE and CV events on JAKi therapy.

Risk Factors 40

Risk Factors Article 40

DAIC

FEBRUARY 29, 2024

24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 Atrial Fibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

Journal of Cardiovascular Pharmacology

NOVEMBER 3, 2023

Modifiable risk factors, such as hypertension and dyslipidemia can be managed through lifestyle and pharmacotherapy treatments to reduce the risk of primary and secondary major cardiovascular events in patients with elevated risk. Abstract: Cardiovascular disease continues to be the leading cause of mortality globally.

Risk Factors 40

Risk Factors Cardiovascular Disease Article Hypertension 40

Journal of Cardiovascular Pharmacology

SEPTEMBER 12, 2024

Lipoprotein(a) [Lp(a)] is a risk factor for coronary disease. Lipoprotein(a) [Lp(a)] is a risk factor for coronary disease. Although levels are primarily genetically determined, data from patients with inflammatory diseases indicate that the inflammatory milieu is associated with increased Lp(a) levels.

Risk Factors 40

Risk Factors 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

There was no difference between the ALT and TNK cohorts in their baseline demographic characteristics or premorbid vascular risk factors. Of the 165 patients undergoing thrombolysis, 75 also underwent EVT, with 55 patients treated with ALT compared to 20 patients treated with TNK.

Thrombolysis 40

Thrombolysis Pharmacology Risk Factors Strokes 40

Cardiometabolic Health Congress

JANUARY 3, 2024

Concluding Thoughts With the increased interventions of promising weight loss drugs not just for weight reduction, but also for improvement in associated risk factors, patients and providers are offered renewed hope.

Obesity 97

Obesity Diabetes Blood Pressure BMI 97

Journal of Cardiovascular Pharmacology

OCTOBER 21, 2024

Cardiac hypertrophy is a crucial risk factor for heart failure when the heart is confronted with physiological or pathological stimuli. Cardiac hypertrophy is a crucial risk factor for heart failure when the heart is confronted with physiological or pathological stimuli.

Physiology 40

Physiology Heart Failure Risk Factors Article 40

Cardiometabolic Health Congress

JULY 25, 2023

Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1]

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Dr. Sanjay Gupta

MARCH 6, 2022

Fourthly, we need to educate the patient on the condition in jargon-free and reassuring language on what risk factors and lifestyle choices may have led to the development of the condition and on practical ways to modify those risk factors as aggressively as possible. The next step is to talk about treatments.

Chronic Disease 40

Chronic Disease Quality of Life Heart Failure Nursing 40

Dr. Smith's ECG Blog

APRIL 8, 2016

Crit Care Med 1991; 19:694) Concentrated Potassium Chloride Infusions in Critically Ill Patients with Hypokalemia The Journal of Clinical Pharmacology. Furthermore, these results were independent of the patient's underlying renal function or associated diuretic administration.

STEMI 52

STEMI Myocardial Infarction Cardiac Arrest Arrhythmia 52

Stroke Journal

FEBRUARY 27, 2024

Currently, there are no specific pharmacological treatments for CSVD, and the use of conventional antidementia drugs is not recommended. Mechanistic pathways underlying the neurocognitive benefits of exercise include the control of vascular risk factors, improving endothelial function, and upregulating exerkines.

Dementia 40

Dementia Exercise Pharmacology Risk Factors 40

DAIC

FEBRUARY 7, 2024

Meschia is a pioneer in the study of inherited risk factors for ischemic stroke and has had a longstanding commitment to providing the latest evidence for carotid revascularization as a means for stroke prevention. Meschia is certified by the American Board of Psychiatry and Neurology (ABPN) in neurology and vascular neurology.

Strokes 105

Strokes Stroke Research Health Disparities 105